Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 13,937 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103), Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more

Conditions: Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Interventions: Miro3D Wound Matrix, Standard of Care; Device · Other
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Coconut Creek, Florida • Coral Gables, Florida + 9 more

Conditions: Heart Failure
Interventions: PAC provision at hospital discharge, Control non-intervention; PAC without filter; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Psoriasis Vulgaris, Topical Administration
Interventions: Total coumarin (TC) cream, Vehicle; Drug
Lead sponsor: Psoriasis Research Institute of Guangzhou; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York • Seattle, Washington

Conditions: Sleep Disturbances in Perimenopause
Interventions: Brahmi-Gotukola oil padabhyanga, Sesame oil Padabhyanga; Behavioral
Lead sponsor: Saipriya Gowrishankar; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fairfield, Iowa

Conditions: Food Preferences, Obesity, Weight Gain
Interventions: Exposure to calorie information, Exposure to healthy labels only, Exposure to healthiness information, Exposure to physical activity equivalents, Exposure to "high in" nutrient warning labels; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8,145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: This Study Will Evaluate Whether TXA Reduces Pain
Interventions: Tranexamic acid, placebo; Drug · Other
Lead sponsor: St. Louis Joint Replacement Institute; Other
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bridgeton, Missouri

Conditions: Acute Coronary Syndrome
Interventions: Decision Aid; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3556050, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 35
States / cities: Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 28 more

Conditions: Pulmonary Disease, Chronic Obstructive, Exercise
Interventions: tiotropium 18 mcg, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 21
States / cities: Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Total Knee Arthroplasty
Interventions: Suzetrigine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Obesity, Insulin Resistance, Inflammation
Interventions: Colchicine, Placebo; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fibromyalgia
Interventions: Cognitive Behavior Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions: BI 770371, Placebo for BI 770371; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Coronado, California • Montclair, California + 8 more

Conditions: Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions: Expect Respect, Enhanced Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years to 15 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Aneuploidy, Genetic Counseling, Informed Consent, Decisional Conflict
Interventions: Video Educational Tool Regarding Prenatal Genetics; Other
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Complications; Cesarean Section
Interventions: Vaginal Cleansing, Abdominal Cleansing; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Female only
Enrollment: 608 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Solid Tumor, Adult, Metastasis
Interventions: Palliative and Survivorship Care Model; Behavioral
Lead sponsor: Good Samaritan Hospital Medical Center, New York; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: West Islip, New York

Conditions: Hiv, Sexual Health
Interventions: Parents and Adolescents Talking about Healthy Sexuality (PATHS), Lead with Love (LWL); Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 14 Years and older
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pressure Injuries, Pressure Ulcer Prevention
Interventions: A gamified mobile learning, Booklet training; Device · Other
Lead sponsor: Mehmet Akif Ersoy University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraceptive Usage, Contraceptive Behavior, Chronic Disease, Chronic Condition, Chronic Conditions, Multiple
Interventions: My Health, My Choice Web-Based Contraceptive Decision Tool, Usual Contraceptive Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Pomona, California • Nampa, Idaho + 14 more

Conditions: Breast Cancer
Interventions: Elacestrant, Standard of Care; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 104
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Fullerton, California + 84 more

Conditions: Type 2 Diabetes, Neuropathy, Painful, Chronic Low-back Pain, Lumbar Disc Herniation
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers

Project 4: ACHIEVE PATHFINDER

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)

A Study Comparing the Effects of Two Types of Natural Oils Used in a Bedtime Foot Massage Routine on Sleep and Emotional Well-Being in Perimenopausal Women.

Online Food and Beverage Labels and Vending Machine Selections

Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial

Impact of a Decision Aid on Patient Decision Making in Emergency Department Chest Pain Patients

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

Tiotropium In Exercise

A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee Arthroplasty

Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity

Promoting Health in People With Fibromyalgia

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

Expect Respect Middle School Randomized Trial

GEM: Impact of a Video Education Tool on Decisional Conflict Among Prenatal Patients

Vaginal Cleansing Before Cesarean Delivery to Reduce Infection

Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer

Parent-focused Intervention to Reduce HIV Risk in Gay and Bisexual Adolescents

Gamified Learning for Pressure Injury Prevention

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Methylglyoxal Evaluation in Humans